A molecular modelling study on the human cytochrome P450-mediated metabolism of tamoxifen is reported. Using three-dimensional models of human P450s constructed from the bacterial crystal structure template, P450 bm3 (CYP102), the likely mode of substrate binding is demonstrated, which is consistent with the known positions of metabolism in tamoxifen. In particular, the CYP102-derived structures of CYP3A4, CYP2D6 and CYP2C9 are able to rationalize the routes of tamoxifen metabolism reported in human subjects. The implications for potential toxicity of tamoxifen in man is discussed in the light of these findings.
Introduction
There is current interest in the use of the anti-oestrogenic compound tamoxifen for the treatment of post-menopausal breast cancer and the prevention of breast cancer, osteoporosis and heart disease (1). Although toxic effects have been demonstrated in rodent species, it is thought that these may not have relevance to human subjects, due to significant species differences in metabolism. Most phase I metabolism is mediated by one or more of the cytochromes P450 (CYP*) and the relevant human P450 isoforms involved in the metabolism of tamoxifen have recently been reported (2), indicating that the major pathways of tamoxifen metabolism are mediated via CYP3A and CYP2C isoforms, which together constitutẽ 50% of the human hepatic P450 complement; the average percentages of various P450s in human hepatic samples (3) are shown in Table I .
As molecular models of the major human P450s have recently been published (4) (5) (6) , based on the new bacterial P450 crystal structure, P450 bm3 (CYP102), it is of interest to investigate whether the tamoxifen molecule is able to fit the relevant putative enzyme active sites in such a way as to explain the known experimental findings on P450-mediated metabolism. It is important to develop models which may assist in the prediction of xenobiotic metabolism (7) and the structural characteristics of specific P450 substrates and inhibitors can be useful guidelines in such investigations (8) . In particular, the involvement of enzymes from the CYP2C and CYP2D subfamilies, which exhibit genetic polymorphism in man (9) , may represent significant limitations on the clinical use of novel pharmaceutical products in sections of certain ethnogeographical groups, whereas other P450 families, especi-
•Abbreviations: CYP, cytochrome P450; PM, 'poor metabolizer'; EM, 'extensive metabolizer'. © Oxford University Press ally CYP1 (10) , have been shown to play a major role in the metabolic activation of procarcinogens and mutagens, including chemicals to which man is likely to be exposed.
The metabolism of tamoxifen has been studied in small rodents (11) and in human liver (2, (12) (13) (14) (15) . Although known to exhibit genotoxicity, mutagenicity and carcinogenicity in animal and other test systems, the possible link between tamoxifen therapy and human cancers is controversial, despite an apparent correlation between tamoxifen usage and endometrial cancer (16) . There is clear structural similarity between tamoxifen and the potent carcinogen diethylstilbestrol, but it is likely that the relatively high clearance of tamoxifen, resulting from addition of the /V-dimethylaminoethoxy side chain, will diminish the potential toxic risk to man, especially as the important Af-dimethylation step is catalysed by CYP3A4, which is the major component (see Table I ) of the human hepatic P450 complement (3) . Enzymes of the CYP2C subfamily also constitute a relatively high percentage of human P450 in the liver and it would appear that of these, 2C9 mediates 4-hydroxylation of tamoxifen (2), although 2D6 may also be involved in this pathway, despite conflicting evidence (2, 15, 17) . The likely role of P450 enzymes from the CYP2C and CYP2D subfamilies in phase I metabolism of tamoxifen could have important implications for prescribing this anti-estrogen to patients who exhibit 'poor metabolizer' (PM) status with respect to 2D6 or 2C19 genetic polymorphisms. Furthermore, production of the 4-hydroxy metabolite represents the route to the active anti-estrogenic agent and it has been shown that 4-hydroxy tamoxifen is able to bind at an interaction site close to the surface of the human oestrogen receptor (18) . Apparently, the 'extensive metabolizer' (EM) phenotype for CYP2D6-mediated debrisoquine metabolism has been associated with lung cancer incidence in several human ethnogeographical populations (19) and it is possible that CYP2D6-catalysed activation of the nicotine pyrolysate NNK could represent a link between tobacco smoking, lung cancer and the 2D6 EM phenotype (20). However, in the case of tamoxifen the 4-hydroxylation step, which is thought to be catalysed by both CYP2C9 and, to a lesser extent, CYP2D6, can be regarded as a potentially detoxifying process and it is not clear whether the metabolic activation of tamoxifen (i.e. epoxidation of the alkene moiety) is relevant to man. Recent evidence suggests that the activation of tamoxifen in Homo sapiens may involve 4-hydroxylation and/or a-hydroxylation of the ethyl group, as these can both give rise to DNA adducts (21) , whereas transacts isomerization of the 4-hydroxy metabolite could represent an important step in the pathway to activation (17) .
Materials and methods
The construction of three-dimensional models of mammalian cytochromes P450 based on the CYP102 template has been described previously (4, 5) . The human cytochromes P450 reported in this work were produced from the CYP102 crystal structure (Brookhaven Protein Databank, reference code 2hpd) using a novel amino acid sequence alignment, which included consideration of site-directed mutagenesis and other experimental evidence (4). It has been shown that a model of the human isoform CYP2A6 is able to rationalize coumarin metabolism in man, in addition to explaining substrate specificities in the rat and mouse CYP2A orthologues (5). The putative active sites of these and other mammalian P450s modelled via the same procedure are consistent with the information obtained from protein engineering studies regarding the effect of certain amino acid residues on P450 substrate specificity and regioselectivity (4, 5) . Alignment with the CYP 102 sequence exhibits higher overall homology with mammalian microsomal P450s than those obtained using the CYP 101 template (22) , especially when the results from site-directed mutagenesis experiments, molecular probe analysis and other experimental data are taken into account. For example, the sequence identity between CYP102 and CYP3A4 is 27.1%, whereas for CYP10I and CYP3A4 this is significantly 1358 Fig. 3 . A possible mode of interaction between tamoxifen and the putative active site of CYP2D6. Specific amino acid residues which may be associated with substrate binding and metabolism (Thr268) are labelled. Tamoxifen is orientated for oxygenation in the 4-position via contacts with Glul84, Glu78, Phe87 and Val328. lower at 16.7%. CYP102 can be regarded as the preferred template for microsomal P45Os (23) due to the fact that there is a commonality in redox partner, as all utilize an NADPH-dependent oxidoreductase and, therefore, CYP 102 has been classified as belonging to the eukaryotic class of P450s (24) . Moreover, in contrast to either CYP101 or CYP108, there are relatively few residue insertions required for the generation of microsomal P450 structures via alignment with CYP102, which considerably facilitates the modelling process. Following the necessary residue changes, as required by the alignment (4), geometry optimzation of the raw structures gave minimum energy values of -1000 kcal/mol for the human P450 models investigated (4, 5) . The minimized tamoxifen structure was then docked interactively into the putative active sites of the relevant P450s thought to be involved in its metabolism, using the Sybyl molecular modelling software system (Tripos Associates, St Louis, MO). Figure 1 shows the proposed mode of interaction between tamoxifen and the putative active site region of CYP3A4. It appears that hydrogen bonding between Asn74 and the oxygen atom of the ethanolamino side chain, together with n-K stacking between the phenyl ring of Phe72 and one of the aromatic rings will orientate tamoxifen for A/-demethylation. One of the iV-methyl groups is relatively close to the heme iron and, although the distances involved are slightly different from those encountered with typical CYP3A4 substrates (25) , this orientation certainly explains the known CYP3A4-mediated metabolism of tamoxifen in terms of key interaction points found with many CYP3A4 substrates. There is also a close hydrophobic contact between one of the putative active site aliphatic amino acid residues and the ethyl group of tamoxifen, which gives further support to this model of the enzyme-substrate interaction. However, one of the aromatic rings is rather close to Thr73, which would not be regarded as favourable, although it is possible that the substrate may move closer to the heme following this initial binding interaction and this could then involve JI-JI stacking between this aromatic ring and Phe72, a significantly more favoured Distance between the N-methyl group (site of 3A4 metabolism) and the iron-oxygen of the heme moiety Distance between the side chain oxygen atom, which forms a hydrogen bond with Ser331, and the 4-hydroxyl group Distance between the 4-hydroxyl (site of 2C9 metabolism) and the iron-oxygen of the heme moiety Distance between the protonated nitrogen atom on the side chain, which ion pairs with Glul84, and the 4-hydroxyl group Distance between the 4-hydroxyl (site of 2D6 metabolism?) and the iron-oxygen of the heme moiety a The distances between key interacting atoms of the tamoxifen substrates and sites of metabolism are within the ranges encountered with other substrates of these enzymes, with the exception of 2D6, although a known 2D6 substrate, tropisetron, shows a similar distance value. 'The interactions between the tamoxifen molecule and each enzyme active site amino acid residues and heme groups are shown in Figures 1-3 . interaction in energy terms. Furthermore, such a movement of the substrate would bring the /V-methyl group nearer to the heme iron, thus facilitating oxygenation and N-demethylation.
Results and discussion
As the active site of CYP3A4 is relatively large, it is possible that there may be alternative docking interactions for tamoxifen, especially as one side of the heme pocket appears to contain a number of aromatic amino acid residues that would be expected to be capable of binding tamoxifen via its phenyl ring moieties. However, the orientation shown in Figure 1 is consistent with the typical structural requirements for CYP3A4 substrates in terms of interactions with Asn74, Phe72 and one of the active site hydrophobic residues, together with the distances between interacting groups and the site of metabolism.
The possibility of 4-hydroxylation of tamoxifen being mediated by CYP2C9 was postulated on the grounds of structural modelling within the enzyme active site, prior to publication of the relevant human P450 studies of White and co-workers (2). The reason for this speculation was the distance between the hydrogen bond acceptor atom (i.e. the oxygen of the ethanolamine side chain) and the site of metabolism at the 4-position. Moreover, modelling of tamoxifen within the putative active site of CYP2C9 indicates that p-hydroxylation is likely on the grounds of orientation of the substrate with respect to Ser331, a known site of interaction for 2C-specific compounds (4). Furthermore, p-hydroxylation of the aromatic rings is a common feature of CYP2C-mediated metabolism, e.g. phenytoin and mephenytoin. Confirmation of this hypothesis by the experimental work of White et al. (2) clearly builds confidence in the use of enzyme modelling as a means of predicting the route of P450-catalysed metabolism. The likely interaction between tamoxifen and the CYP2C9 model is shown in Figure 2 , where it can be seen that hydrogen bonding from Ser331 to the oxygen of the side chain orientates the substrate for hydroxylation at the 4-position on the relevant phenyl ring. There are other interactions between the substrate and putative active site residues which augment this mode of binding, such as hydrophobic contacts between the N-dimethyl group on the substrate and the side chain of Leu332, and between the ethyl group on tamoxifen and Val87, together with n-Tt stacking between one of the aromatic rings on the substrate and Phe88. It has been demonstrated via site-directed mutagenesis experiments that Ser331 is an important determinant of substrate regioselectivity in the CYP2C subfamily (26, 27) .
In addition to the involvement of. CYP2C9 in 4-hydroxylation of tamoxifen, there is also some evidence for the CYP2D6 isozyme catalysing the same reaction (2) . The distance between the protonatable nitrogen atom in tamoxifen and the para position on the adjacent aromatic ring is > 12 A, which is 5 A greater than the upper limit for CYP2D6 substrate specificity according to the currently accepted template model (28) . Consequently, there has to be some refinement of this CYP2D6 model to account for these findings. In the structure of CYP2D6 generated from CYP102 (4, 29, 30) it is possible that tamoxifen can occupy the putative active site with an orientation that presents the para position on the appropriate aromatic ring for oxygenation, as shown in Figure 3 . In order to rationalize the known CYP2D6-mediated route of metabolism the tamoxifen molecule has to be orientated differently from that of other typical substrates of this isoform. However, the CYP2D6 substrate tropisetron does exhibit some analogy with tamoxifen in terms of the distance of the protonated nitrogen from the site of metabolism (30) . This involves ion pairing with Glu 184, instead of the usual Asp260 (Asp301 in CYP2D6), together with somewhat different interactions with other active site residues. Although there is to date no evidence from site-directed mutagenesis for the possible role of Glu 184 in CYP2D6 substrate binding, this position is close to that shown by Lindberg and Negishi (31) to be critical for substrate specificity in the mouse CYP2A orthologues. Molecular modelling of CYP2A subfamily isozymes indicates that both positions 181 and 184 are involved in substrate binding interactions and orientation for metabolism in the experimental observations (5), whereas residue 180 (212 in CYP2D6) corresponds to an allelic variant (Gly-»Glu) in 2D6, which is associated with lowered debrisoquine metabolism. Consequently, there is some evidence that residues on the F helix, situated above the heme binding site, may be associated with substrate binding interactions in the CYP2 family and, furthermore, position 182 in the model (4) corresponds to Thrl85 in CYP101, which has been shown by site-directed mutagenesis to be important for substrate regiospecificity (32, 33) . Table II summarizes the relevant interatomic distances in tamoxifen and with respect to its interaction with the putative active sites of CYP2D6, CYP2C9 and CYP3A4. It is not known which P450 isoform is responsible for ahydroxylation of the ethyl group, but preliminary modelling studies (data not shown) indicate that tamoxifen is able to fit the putative active site of CYP2B6, where interactions with complementary amino acid side chains could orientate the molecule for oxygenation at the a-position on the ethyl moiety. However, this is a minor pathway in man and CYP2B6 constitutes a very low percentage of human hepatic P450.
Although one might expect that 4-hydroxylation of tamoxifen represents a detoxifying pathway, as conjungation reactions with the phenolic group would be possible, there is recent evidence (21) which suggests that this step is actually a potentially activating route of metabolism. If this is the case, then the CYP2C9-and CYP2D6-mediated pathways could have some relevance to a possible carcinogenic risk from tamoxifen use in human populations, particularly with respect to genetic polymorphism in either of these human P450 isoforms. (Although the association between genetic defects in CYP2D6 and CYP2C19 and lowered metabolism have been established, there is evidence to suggest that allelic variants of 2C9 may also give rise to PM status). It remains to be seen whether any linkage exists between cancer incidence associated with tamoxifen use and PM or EM phenotypes of CYP2D6 or CYP2C19. However, the detoxifying role of CYP3A4, the major human hepatic isoform, in the metabolism of tamoxifen probably explains the fact that, in contrast to the situation in experimental rodents, the potential carcinogenic risk is likely to be relatively low.
